2.16
+0.03(+1.41%)
Currency In USD
| Previous Close | 2.13 |
| Open | 2.11 |
| Day High | 2.19 |
| Day Low | 2.1 |
| 52-Week High | 5.64 |
| 52-Week Low | 1.9 |
| Volume | 415,483 |
| Average Volume | 804,522 |
| Market Cap | 145.42M |
| PE | -2.73 |
| EPS | -0.79 |
| Moving Average 50 Days | 2.19 |
| Moving Average 200 Days | 2.9 |
| Change | 0.03 |
If you invested $1000 in Cardiff Oncology, Inc. (CRDF) 10 years ago, it would be worth $5.18 as of December 04, 2025 at a share price of $2.15. Whereas If you bought $1000 worth of Cardiff Oncology, Inc. (CRDF) shares 5 years ago, it would be worth $103.61 as of December 04, 2025 at a share price of $2.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 12:00 PM GMT
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
GlobeNewswire Inc.
Oct 02, 2025 8:05 PM GMT
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 28, 2025 8:05 PM GMT
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will